Rekisteröidy luodaksesi hälytyksiä instrumenteille,
taloustapahtumille ja seuraamiesi kirjoittajien sisällölle
Rekisteröidy ilmaiseksi Onko sinulla jo tili? Kirjaudu
Lainaukset
Kaikki instrumenttityypit
- Kaikki instrumenttityypit
- Indeksi
- Pääoma
- ETF:t
- Varat
- Hyödyke
- Valuutat
- Krypto
- Joukkov.
- Sertifikaatit
Yritä tehdä uusi haku
🟢 Markkinat ovat nousussa. Jokainen 120K+-yhteisömme jäsen tietää, miten toimia. Sinäkin voit tietää.
Hyödynnä 40 %:n ale
Eventide Healthcare & Life Sciences Fund Class I Shares (ETIHX)
Lisää salkkuun / Poista salkusta
Lisää salkkuun
34,20
-0,61
-1,75%
- Morningstar-luokitus:
- Varat yhteensä: 1,18B
Eventide Healthcare & Life Sciences I
34,20
-0,61
-1,75%
ETIHX - yleiskatsaus
Tältä sivulta löytyy syväluotaava Eventide Healthcare & Life Sciences Fund Class I Shares-profiili. Saat lisätietoja ETIHX-avainjohtajista, -kokonaisvaroista, -sijoitusstrategiasta ja -yhteystietoista.
Yhteystiedot
Ylin johto
| Nimi | Otsikko | Vuodesta | Saakka |
|---|---|---|---|
| Finny Kuruvilla | Resident | 2012 | now |
| Elämäkerta | Finny Kuruvilla, MD, PhD, serves as a Co-Chief Investment Officer, Senior Portfolio Manager for Eventide’s mid-cap growth and healthcare & life sciences strategies, a Managing Director for Eventide’s private fund, as well as Founding Member of Eventide. Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech. | ||
| Kyle Rasbach | Portfolio Manager | 2023 | 2024 |
| Elämäkerta | Kyle Rasbach, PhD, PharmD, joined Eventide in April 2022, and has led Eventide’s Healthcare team across all Eventide Investment products since June 2022 under the supervision of the Adviser’s Co-Chief Investment Officers. Dr. Rasbach has served as a Managing Director for the Eventide Healthcare Innovation Fund I, LP, since November 2022. Dr. Rasbach has extensive experience in clinical pharmacology, basic science, and healthcare equity research. Prior to joining Eventide, Dr. Rasbach was a Managing Partner at Pappas Capital, a life science venture capital firm that invests across biotechnology, biopharmaceuticals, drug delivery, and medical devices, from 2017-2022. Earlier in his career he was an equity research analyst and Vice President at T. Rowe Price from 2013-2017, where he managed pharmaceutical, specialty pharmaceutical, and biotechnology investments. Prior to joining T. Rowe Price, Dr. Rasbach was an equity research associate and Vice President at Cowen and Company from 2010-2013, where he covered global pharmaceutical equities. Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences as well as a PharmD from the Medical University of South Carolina; he completed his postdoctoral training in the laboratory of Bruce Spiegelman at the Harvard Medical School. He also holds an MBA from The Citadel and a BS in Biology from Denison University. | ||
| Joy Ghosh | Portfolio Manager | 2022 | 2022 |
| Elämäkerta | Dr. Joy Ghosh has served the Adviser as a Portfolio Manager since January 2022 and Senior Analyst since 2020. Prior to joining the Adviser, Dr. Ghosh was Vice President of Bain Capital from 2019 to 2020 and an Associate of Bain Capital from 2017 to 2019. Dr. Ghosh holds a PhD from the University of Washington, Seattle in Biomolecular Structure and Design and a bachelor’s degree in Biochemistry from the University of Texas at Austin. | ||
Kirjoita ajatuksiasi kohteesta Eventide Healthcare & Life Sciences Fund Class I Shares
Haluatko varmasti poistaa tämän graafin?
Poista Peruuta
Korvaa liitteenä oleva graafi uudella graafilla?
Korvaa Peruuta
Ohjeita kommentoimiseen
Lisää graafi kommenttiin
Vahvista esto
Haluatko varmasti estää käyttäjän %USER_NAME%?
Toimiessasi näin sinä ja %USER_NAME% ette voi nähdä toistenne Investing.com-julkaisuja.
Käyttäjän %USER_NAME% lisääminen estoluetteloosi onnistui
Koska olet juuri poistanut eston tämän henkilön kohdalla, sinun täytyy odottaa 48 tuntia ennen estämisen uusimista.
Raportoi tämä kommentti
Mielestäni tämä kommentti on:
Kommentti merkitty
Kiitos!
Raporttisi on lähetetty moderaattoreidemme tarkastettavaksi